Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
NEPAFOX
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
- NCT02172976 ↗
- Completed
- Krankenhaus Nordwest
- Focused
We haven't built an HCP commentary report on NEPAFOX (FOLFIRINOX in resectable pancreatic cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEPAFOX so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer
- Phase
- Phase 2/Phase 3
- Status
- Completed
- Conditions
- Resectable Prancreas Carcinoma
- Interventions
- Gemcitabine; Oxaliplatin; 5-Fluorouracil; Irinotecan; Natriumfolinate
- Arms
- FOLFIRINOX · Experimental
- Gemcitabine · Active comparator
- Enrollment
- 40
- Primary outcomes
- median overall survival
- Sponsor
- Krankenhaus Nordwest
- Start
- Nov 2014
- Primary completion
- Jan 2020
- Results posted
- No
- Registry record
- NCT02172976 · updated Sep 2, 2020